

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): May 2, 2022

AVALON GLOBOCARE CORP.
(Exact name of registrant as specified in its charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-38728
(Commission File Number)

47-1685128
(IRS Employer
Identification Number)

4400 Route 9 South, Suite 3100, Freehold, New Jersey 07728
(Address of principal executive offices) (zip code)

646-762-4517
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

		Name of each exchange on
Title of each class	Trading Symbols	which registered
Common Stock, \$0.0001 par value per share	AVCO	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

☐ Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

Avalon GloboCare Corp. (the “Company”) plans to present and/or distribute to the investment community and utilize at various industry and other conferences the presentation slides attached hereto as Exhibit 99.1.

The furnishing of the attached presentation is not an admission as to the materiality of any information therein. The information contained in the slides is summary information that is intended to be considered in the context of more complete information included in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) and other public announcements that the Company has made and may make from time to time by press release or otherwise. The Company undertakes no duty or obligation to update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosures. For important information about forward looking statements, see the slide titled “Forward Looking Statements” in Exhibit 99.1 attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 7.01 and in the presentation attached as Exhibit 99.1 to this Current Report shall not be incorporated by reference into any filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits

Exhibit No.	Description
99.1	Company Slide Presentation
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AVALON GLOBOCARE CORP.

Dated: May 2, 2022

By: /s/ Luisa Ingargiola
Name: Luisa Ingargiola
Title: Chief Financial Officer



AVALON
GLOBOCARE CORP.

Corporate Presentation

May 2022

www.avalon-globocare.com

Nasdaq: AVCO

Forward-Looking Statements

Certain statements contained in this presentation may constitute “forward-looking statements”, which provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors as disclosed in our filings with the Securities and Exchange Commission located at their website (<http://www.sec.gov>). In addition to these factors, actual future performance, outcomes, and results may differ materially because of more general factors including (without limitation) general industry and market conditions and growth rates, economic conditions, and governmental and public policy changes. The forward-looking statements included in this presentation represent the Company's views as of the date of this presentation and these views could change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this presentation.

Corporate Overview and Highlights

Mission: Avalon GloboCare Corp. (Nasdaq: AVCO) is a clinical-stage biotechnology company dedicated to develop and deliver innovative and transformative CellTech with multifunctional convergence in cellular technologies/therapeutics, precision diagnostics and intellectual property in the field of immuno-oncology and cellular medicines

History: Founded in 2016; successfully uplisted to Nasdaq in December 2018; Headquarters in Freehold, NJ; approx. 20 FTEs (including subsidiaries)

Core Technology Platforms:

- **Cellular Immunotherapies**
including CAR-T, mRNA-based FLASH CAR™
- **Avalon Clinical-Grade Tissue-Specific Exosomes (ACTEX™)**
- **AVA-Trap™**
QTY Code-derived Decoy Receptors / Hemofiltration System / Novel Therapeutic Targets
- **Precision Companion Diagnostics**



Nasdaq: AVCO

3

Corporate Overview and Highlights

Leveraging platform through strategic partnering opportunities with academia and industries complementary to our R&D programs

- Massachusetts Institute of technology
- University of Pittsburgh Medical Center
- Arbele Limited
- HydroPeptide, LLC

Strong Intellectual Property Portfolio:

Underpinning Avalon's R&D pipeline is a broad and deep intellectual property portfolio, covering a number of key enabling technologies and addressing multi-billion dollars of unmet CellTech market worldwide



Nasdaq: AVCO

4

Senior Management, Board of Directors, Advisors

Board of Directors

Daniel Lu
Chairman of the Board

Congressman Billy Tauzin
*Director; Former U.S. Congressman;
Former President of PhRMA*

David Jin, M.D., Ph.D.
Director, CEO, President

Tevi Troy, Ph.D.
*Director; Chairman of Nomination/Governance Committees
Former Deputy Director of U.S. Human Health Services*

Yancen Lu
*Director, Chairman of Compensation Committee
Founder and Managing Director, Pagoda Tree Group*

Steven Sanders, J.D.
*Director, Co-Chair of Compensation Committee
Founder of Ortoli Rosenstadt Law Firm, NYC*

William Stilley
*Director, Chairman of Audit Committee
CEO, Adial Pharmaceuticals (Nasdaq:ADIL)*

Yue Charles Li
Director, M&A Taskforce

Senior Management Team

David Jin, M.D., Ph.D.
*CEO, President, Co-founder, BoD
U.S. Licensed Physician; Former Medical Resident, Fellow and Faculty
Member at Weill Cornell Medicine and New York-Presbyterian
Hospital; Senior Clinician-Scientist at Ansary Stem Cell Institute;
Former CMO of BioTime Inc. and OncoCytte Corporation*

Meng Li
*COO
Former WPP Group's company executive*

Luisa Ingargiola, MHA
CFO, Former CFO and BoD of several U.S. Public companies

Anna Azvolinsky, Ph.D.
Head, Media and Communication

Angela An
Vice President, APAC Business Development

Professor Daopei Lu, M.D.
Scientific Founder

Team of Our Subsidiaries

David Jin, M.D., Ph.D.
CEO, Avactis (JV with Arbele)

John Luk, M.D., D.Sc.
President, Avactis

Steven Sukel, J.D.
Managing Director, Avalon RT9 Properties, LLC
Lucy Lu
President, Nanjing Epicon Biotech co., Ltd.

Scientific & Clinical Advisory Board

Robert S. Langer, Sc.D. -- Massachusetts Institute of Technology; David H. Koch Institute Professor
Yen-Michael Hsu, M.D., Ph.D. -- University of Pittsburgh Medical Center, Chief of Cellular Therapy
Peihua Peggy Lu, M.D. -- Executive President, Lu Daopei Hospital
Dongfang Liu, Ph.D. -- Rutgers New Jersey Medical School; Director of Immunoassay Program
Hongxing Liu, M.D., M.S. -- Lu Daopei Hematology Institute, Executive President
Uwe B. Sletyr, Ph.D. -- Professor Emeritus, University of Natural Resources and Life Sciences
Full Member, Austrian Academy of Sciences



Nasdaq: AVCO


5

Key Differentiators



Differentiator: Broad Spectrum of Immune Effectors

Avalon's Cellular Medicine Pipeline Candidates: Targeting Broad Bandwidth of Immuno-Oncology



Differentiator: Seamless Integration of Vertical Segments

Innovative Research, Novel Targets /
Delivery, Strong IP Protection

cGMP Bioprocessing & Bioproduction Capabilities,
QC/QA, Accreditation (FACT, aaBB, CAP)

Clinical Trial (IIT, IND) Infrastructure,
Seasoned Medical Team & CRA

Upstream

Midstream

Downstream

- ↑ Better and Safer
Therapeutic Options
- ↓ Bio-manufacturing
Time & Cost
- ↑ Patient Accessibility
- ↑ International Multi-
Center Clinical Trials

CAR-T and FLASH-CAR™ Cell Therapy



AVA-001 (4-1BB anti-CD19 CAR-T)

FIRST GENERATION CAR-T

Novartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice

Aug 30, 2017

Gilead to buy Kite Pharma in \$11.9 billion deal
PUBLISHED MON, AUG 28 2017 - 8:27 AM EDT - UPDATED MON, AUG 28 2017 - 10:00 PM EDT


FDA approves Yescarta from Gilead's Kite

BY DAVID SALAZAR

October 15, 2017

Avalon's 3rd Generation CAR-T:

- AVA-001, anti-CD19 CAR-T
- Co-developed with China Immunotech Co. Ltd.
- 4-1BB co-stimulatory signal driven
- Better cancer-killing efficacy
- Shorter bioproduction time



- Pre-clinical studies completed at end of Q2 2019
- Successfully obtained IRB approval in Aug 2019
- Initiated first-in-human clinical trial at LuDaopei Hospital on Aug 15, 2019
- ClinicalTrial.gov Identifier: NCT03952923

AVA-001 (4-1BB anti-CD19 CAR-T)

Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001

PRESS RELEASE GlobeNewswire
17 Jun. 29, 2020, 03:30 PM

- Completed Phase I Clinical Study of 4-1BB Based Anti-CD19 CAR-T Therapy for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia
- Achieved 90% Complete Remission (CR) Rate with Minimum Toxicity or Adverse Side Effects; Successfully "Bridging" to Allogeneic Bone Marrow Transplant with Curative Intent

This paradigm of bridging CAR T-cell therapy to bone marrow transplant creates a new therapeutic horizon with curative potential for patients with relapsed/refractory B-ALL and other hematologic cancers

Pilot First-in-Human Clinical Trial Demonstrates:

- Complete Remission (CR) Rate: 90%
- Minimal and well tolerated adverse side effects: no neurotoxicity or > Grade 1 cytokine release syndrome observed
- All patients achieved CR successfully proceeded to allogeneic BMT with curative intent



Nasdaq: AVCO

11

FLASH-CAR™ -- A Multiplex, mRNA-CAR Platform

Bloomberg

Business

Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers

Avalon GloboCare Advances Next Generation Cellular Immunotherapy with FLASH-CAR™ Technology for Blood Cancers

- * RNA-Based Chimeric Antigen Receptor (CAR) Design Compatible with Broad Range of Immune Effector Cells, Including T (CAR-T) and Natural Killer Cells (CAR-NK) Without the Use of Viral Vectors
- * Capable of Targeting Multiple Tumor Antigens for Potentially Superior Therapeutic Effects
- * Rapid 1-2 Day Bio-manufacturing Time to Quickly Meet Treatment Needs in Patients with Relapsed/Refractory Leukemia, Lymphoma and Other Cancer Types
- * First FLASH-CAR™ Candidate, AVA-011, Enters Process Development Phase to Generate Clinical-Grade CAR-T and CAR-NK Cells
- * Joint Filing for Provisional and PCT Patents Completed with Strategic Partner Arbele Limited



Nasdaq: AVCO

12

FLASH-CAR™ -- A Multiplex, mRNA-CAR Platform

Lead Candidate: AVA-011 (Anti-CD19-CD22 CAR-T)

- Autologous or universal CAR T targeting multiple tumor antigens
- Proliferation inducer for in vivo expansion of CAR-T
- Molecular safety switch
- Rapid bio-production time (1-2 days)
- Inducible vector for tumor site specific expression of anti-tumor mediators to induce host response, such as checkpoint inhibitors, activators of Dendritic Cell, T Cells and NK cells

Potential co-activation of tumor-attacking immune cells:

T Lymphocytes

Dendritic Cells

Natural Killer Cells

Currently at IND-enabling process development stage to generate cGMP clinical-grade AVA-011 CAR-T for upcoming first-in-human clinical trial

Universal (“off-the-shelf”) CAR-NK Cell Therapy


Avalon GloboCare expands its cellular immunology program with addition of Chimeric Antigen Receptor-Natural Killer cell therapies

The company said the engineered CAR-NK cells are designed to ‘unmask,’ recognize and destroy a patient’s specific tumor surface targets




Dr. Dongfang Liu

Member of Avalon's SCAB




The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon's lead CAR-T candidate



Nasdaq: AVCO

14

Avalon's Clinical Programs – Timeline and Milestones



Strategic Partnerships



Avalon Academic-Industry Partnership



QTY Protein Design Code to Develop
Decoy Cytokine & Chemokine Receptors
to Combat "Cytokine Storm" and Cancer
Metastasis (AVA-Trap™)

PIs: Shuguang Zhang, Ph.D.
Robert Langer, Sc.D.



Process Development of Clinical-grade AVA-
011 (Flash-CAR™) and ACTEX™ (Exosome-
based Technology)

Co-development of Point-of-Care Automated
PD for Cellular Therapy (PMApsys™)

PI: Yen-Michael Hsu, M.D., Ph.D.



Nasdaq: AVCO


17

Avalon-MIT QTY Code Protein Design Platform


QTY code-generated novel therapeutic targets for cancer immunotherapy and other clinical applications

QTY Code for Protein Design & Modification

* **QTY code** is a genetic modification tool for systematically exchanging (membrane) proteins' primary sequence to regulate its solubility



Designed QTY proteins directly serve as recombinant monoclonal antibodies




Design of the QTY receptors resemble structure of common antibodies

Exchanging the sequence origin (host) of the γ -Fc region can regulate protein's reactivity

- ➡ Novel biopharmaceuticals
- ➡ Novel targets for CAR-T therapy


QTY Proteins as Decoy Receptors



Avalon-MIT QTY Code Protein Design Platform

Avalon GloboCare Achieves Major Milestones Advancing Immunotherapeutic Program towards Combatting Cytokine Storm Associated with COVID-19 Lung Damage and Mortality

- Completed Functional Studies of Six QTY Code Designed Variant Cytokine Receptors as "Molecular Mop" to Remove Excessive Cytokines ("Cytokine Storm") Related to Coronavirus Infection and Cellular Immunotherapy
- Jointly Filed Provisional Patents with Professor Shuguang Zhang's Team of Massachusetts Institute of Technology (MIT)
- Scientific Manuscript Accepted for Publication by the Journal QRB Discovery of Cambridge University Press



AVA-Trap™

QTY Decoy Cytokine Receptors: COVID-19 "Cytokine Storm"

QTY Decoy Chemokine Receptors: Cancer Metastasis



Nasdaq: AVCO

19

Avalon ACTEX™ Platform

(Avalon Clinical-grade Tissue-specific Exosomes)

Accreditation/Standardization
Infrastructures



cGTP

Clinical-Grade
Stem/Progenitor
Cells Bio-production

ACTEX™
(Avalon Clinical-Grade
Tissue-Specific Exosomes)

ACTEX Types

ACTEX Cell-of-Origin

ACTEX Applications

● ACTEX-E	Endothelial Cells (HUVEC), Endothelial Progenitor Cells	→	Wound Management, Skincare, Anti-Scar, Anti-Wrinkle, Anti-Acne, Hair Growth, Orthopedic Application, ...etc
● ACTEX-M	Mesenchymal Stem Cells (Adipocyte/ Umbilical Cord/Umbilical Blood)	→	Wound Management, Skincare, Anti-Scar, Anti-Wrinkle, Anti-Acne, Hair Growth, Orthopedic Application, ...etc
ACTEX-N	Neuronal Stem Cells	→	Neurodegenerative Disorders
ACTEX-BF	Brown Fat Progenitor Cells	→	Weight Management, Metabolic Syndromes
ACTEX-NK	Natural Killer Cells	→	Immune Health; Supplement/Booster to Cellular Immunotherapy
ACTEX-ES	Embryonic Stem Cells (from IVF)	→	Pluripotent Applications

- Currently under co-development and commercialization strategy with HydroPeptide LLC to generate ACTEX-based skin-care and orthopedic products

June 10, 2019

Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization

This milestone marks a pivotal point in Avalon's pipeline, now allowing the company to enter its next phase of commercializing clinical-grade exosome products

Source: PR Newswire



Nasdaq: AVCO

20

Strategic Partnership with HydroPeptide

April 28, 2020 09:00 ET

Avalon GloboCare Partners with HydroPeptide, a Leader in Epigenetics Skin Care, to Accelerate Regenerative ACTEX™ Product Development and Commercialization

- *Focused on Novel Combination of Clinical-Grade Exosomes and Hydropeptides for Cosmeceutical and Orthopedic Product Development*
- *Signed Three-Way Material Transfer Agreement between Avalon GloboCare, HydroPeptide and Weill Cornell Medicine*

- Network of over 50 prominent dermatology practice groups
- “Power Serum” hydropeptide formulation with well established marketing channels worldwide
- Signed strategic partnership agreement and MTA; on-going reformulation of clinical-grade ACTEX-HP combination to be initiated at UPMC; anticipate commercialization via HydroPeptide network in Q1 of 2023



Nasdaq: AVCO

21

Avalon GloboCare Positions as Future Powerhouse in Cancer Immunotherapy and Cellular Medicine

CTx

CellTech & Therapeutics

Upstream: Innovation, R&D, IPs

- QTY-code engineered novel targets; AVA-Trap™
- Next-Gen multi-target, RNA-based Flash-CAR™
- Angiogenic Exosomes; ACTEX™

Midstream: Process development, Bio-production, QC/QA

- UPMC: Accredited cGMP/cGTP/FACT/aaBB/CLIA/CAP Facility

Downstream: Clinical Programs

- Medical Team: Lu Daopei Hospital network and over 100 affiliated hospitals, world's single largest BMT and CAR-T treatment center;
- Commercialization: B-to-B model for product development and global marketing (ACTEX™ ecosystem)

CDx

Precision Diagnostics

- Companion Dx
- Personalized Cellular Medicine
- Bio-informatics Databases
- Prognostic Monitoring
- Development and Commercialization of Companion Diagnostic Kits/Systems

IP

Intellectual Property

Broad and deep IP assets and portfolio, with patent coverage across a number of key enabling technologies in CTx and CDx



Nasdaq: AVCO

22

Corporate Council, American Society of Transplantation and Cellular Therapy (ASTCT)



American Society for
Transplantation and Cellular Therapy

Source: www.astct.org

Avalon GloboCare, one of 25 selected members of ASTCT's Corporate Council (2019-present), is dedicated to accelerate global development of cellular medicine

Actinium Pharmaceuticals
Amgen, Inc.
Atara Biotherapeutics
Avalon GloboCare Corp.
Bluebird Bio
Bristol-Myers Squibb Company
Celgene Corporation
Chimerix

Fate Therapeutics
Gamida Cell
Incyte
Janssen Research & Development, LLC
Jazz Pharmaceuticals
Kiadis
Kite, a Gilead Company
Legend Biotech USA Inc.

Lentigen
Merck & Co., Inc.
Novartis
Omeros
OTTR
Pharmacyclics
PhRMA
Sanofi Genzyme
Takeda Oncology



Nasdaq: AVCO

23



AVALON
GLOBOCARE CORP.

Thank You

Contact:

Corporate Address:

Avalon Executive Center
4400 Route 9 South, Suite 3100 Freehold, New Jersey 07728, USA

Phone: +1-732-780-4400

Fax: +1-732-780-5600

Website: www.avalon-globocare.com

IR Email: avco@crescendo-ir.com

www.avalon-globocare.com

Nasdaq: AVCO